The role of pharmacokinetics (PK) and pharmacodynamics (PD) has increased dramatically as anticancer drug discovery and development has shifted towards molecularly-targeted therapies. Increased appreciation of PK/PD relationships has resulted in greater emphasis on generating and analyzing such data, even for agents without defined molecular targets. Recognition of drug-drug interactions and pharmacogenetic differences in drug metabolism, disposition, and susceptibility has increased the need for assays to define relevant polymorphisms and their clinical impact.
The UPCI Cancer Pharmacokinetics and Pharmacodynamics Facility (CPPF) provides accessible, economical, comprehensive, and state-of-the-art pharmacology research services that support preclinical and clinical research programs at UPCI and medical institutions nationwide.
Read more about our services.